Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1

Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an attractive cancer immunotherapeutic target owing to its role in promoting tumoral immune escape. However, drug development has been hindered by limited structural information. Here, we report the crystal structures of hIDO1 in complex with its substrate, Trp, an inhibitor, epacadostat, and/or an effector, indole ethanol (IDE). The data reveal structural features of the active site (Sa) critical for substrate activation; in addition, they disclose a new inhibitor-binding mode and a distinct small molecule binding site (Si). Structure-guided mutation of a critical residue, F270, to glycine perturbs the Si site, allowing structural determination of an inhibitory complex, where both the Sa and Si sites are occupied by Trp. The Si site offers a novel target site for allosteric inhibitors and a molecular explanation for the previously baffling substrate-inhibition behavior of the enzyme. Taken together, the data open exciting new avenues for structure-based drug design.Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an immunotherapeutic target for cancer therapy. Here, the authors present the substrate-, inhibitor- and effector-bound hIDO1 crystal structures, which give insights into the mechanism and reveal a second small molecule binding site, which is of interest for drug design.

[1]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[2]  M. Bower,et al.  INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology , 2017, ACS medicinal chemistry letters.

[3]  G. Prendergast,et al.  Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. , 2007, Cancer research.

[4]  S. Yeh,et al.  Ferryl Derivatives of Human Indoleamine 2,3-Dioxygenase* , 2011, The Journal of Biological Chemistry.

[5]  K. Morokuma,et al.  ONIOM study on a missing piece in our understanding of heme chemistry: bacterial tryptophan 2,3-dioxygenase with dual oxidants. , 2010, Journal of the American Chemical Society.

[6]  Philip R. Evans,et al.  How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.

[7]  M. Martí,et al.  Complete reaction mechanism of indoleamine 2,3-dioxygenase as revealed by QM/MM simulations. , 2012, The journal of physical chemistry. B.

[8]  G. Prendergast,et al.  Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer , 2014, Cancer Immunology, Immunotherapy.

[9]  L. Tong,et al.  Molecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenase , 2016, Scientific Reports.

[10]  Tingting Xu,et al.  Structural insights into the binding mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943. , 2017, Biochemical and biophysical research communications.

[11]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[12]  K. Morokuma,et al.  Density functional theory study on a missing piece in understanding of heme chemistry: the reaction mechanism for indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase. , 2008, Journal of the American Chemical Society.

[13]  S. Yeh,et al.  Spectroscopic studies of ligand and substrate binding to human indoleamine 2,3-dioxygenase. , 2010, Biochemistry.

[14]  C. Uyttenhove,et al.  Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase , 2012, Proceedings of the National Academy of Sciences.

[15]  E. Raven.  A short history of heme dioxygenases: rise, fall and rise again , 2016, JBIC Journal of Biological Inorganic Chemistry.

[16]  F. Hirata,et al.  Indoleamine 2,3-dioxygenase. Purification and some properties. , 1978, The Journal of biological chemistry.

[17]  D. Rousseau,et al.  Heme Distortion Modulated by Ligand-Protein Interactions in Inducible Nitric-oxide Synthase* , 2004, Journal of Biological Chemistry.

[18]  Tetsuya Kohno,et al.  Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors. , 2014, ACS medicinal chemistry letters.

[19]  J. Shelnutt,et al.  Conserved nonplanar heme distortions in cytochromesc , 1995, Journal of protein chemistry.

[20]  F. Walker,et al.  Ligand-induced heme ruffling and bent no geometry in ultra-high-resolution structures of nitrophorin 4. , 2001, Biochemistry.

[21]  M. Martí,et al.  Evidence for a ferryl intermediate in a heme-based dioxygenase , 2009, Proceedings of the National Academy of Sciences.

[22]  Olivier Michielin,et al.  Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. , 2015, Journal of medicinal chemistry.

[23]  L. Jermiin,et al.  Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. , 2007, Gene.

[24]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[25]  D. Munn,et al.  Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.

[26]  Takashi Otsuki,et al.  Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  O. Hayaishi,et al.  Indoleamine 2,3-dioxygenase. Equilibrium studies of the tryptophan binding to the ferric, ferrous, and CO-bound enzymes. , 1980, The Journal of biological chemistry.

[28]  U. Grohmann,et al.  Different Partners, Opposite Outcomes: A New Perspective of the Immunobiology of Indoleamine 2,3-Dioxygenase , 2012, Molecular medicine.

[29]  C. Piccirillo,et al.  Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives , 2011, Clinical Cancer Research.

[30]  S. Bicciato,et al.  Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells , 2011, Nature Immunology.

[31]  S. Yeh,et al.  Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase. , 2009, Journal of the American Chemical Society.

[32]  J. Dawson,et al.  Heme-Containing Oxygenases. , 1996, Chemical reviews.

[33]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[34]  A. Roitberg,et al.  Structural Study of a Flexible Active Site Loop in Human Indoleamine 2,3-Dioxygenase and Its Functional Implications. , 2016, Biochemistry.

[35]  D. Munn.  Blocking IDO activity to enhance anti-tumor immunity. , 2012, Frontiers in bioscience.

[36]  S. Yeh,et al.  Interactions between nitric oxide and indoleamine 2,3-dioxygenase. , 2006, Biochemistry.

[37]  U. Grohmann,et al.  SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis , 2008, Proceedings of the National Academy of Sciences.

[38]  M. Martí,et al.  The first step of the dioxygenation reaction carried out by tryptophan dioxygenase and indoleamine 2,3-dioxygenase as revealed by quantum mechanical/molecular mechanical studies , 2010, JBIC Journal of Biological Inorganic Chemistry.

[39]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[40]  P. Andrew Karplus,et al.  Linking Crystallographic Model and Data Quality , 2012, Science.

[41]  Su-Ying Wu,et al.  Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1. , 2016, Journal of medicinal chemistry.

[42]  D. Munn,et al.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses. , 2013, Trends in immunology.

[43]  Elizabeth M. Boon,et al.  Probing the function of heme distortion in the H-NOX family. , 2008, ACS chemical biology.

[44]  A. Fersht,et al.  Harnessing Fluorine–Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs , 2016, ACS chemical biology.

[45]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .